Loading
companiesCompany
Acrotech Biopharma
Acrotech Biopharma, part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate (Folotyn), belinostat (Beleodaq) and vincristine liposome (Marqibo).
Overview
Acrotech Biopharma, based in East Windsor, New Jersey, and part of Aurobindo, owns the former Spectrum Pharmaceuticals haematology portfolio: the radioimmunotherapy Zevalin, pralatrexate as Folotyn, belinostat as Beleodaq and vincristine liposome as Marqibo. It acquired Spectrum's marketed products in 2019, including Zevalin, or ibritumomab tiuxetan, for follicular lymphoma, Folotyn and Beleodaq for peripheral T-cell lymphoma, Marqibo and Evomela, a melphalan formulation. OnCo links it to the ibritumomab tiuxetan drug record. Whether the only approved radioimmunotherapy for lymphoma survives commercially in an owner focused on generics is the open question. Ibritumomab tiuxetan has its own page.
Headquarters
East Windsor, New Jersey, US
Scorecard
All companies#46of 1244 companies, score 74
- approved products +30
- targets +2
- modalities +6
- regions +6
- registry trials +30
5 approved, 0 in phase 3, 0 earlier, 1 targets, 1,980 registry studies. Formula on the scorecards page.
Type
Website
ApprovedRadioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)
Ibritumomab tiuxetan · Zevalin
Zevalin is an antibody carrying a radioactive isotope that seeks out CD20 on lymphoma cells. It treats follicular lymphoma that has relapsed and is given as a one-off consolidation after chemotherapy.
ApprovedAntifolate (DHFR inhibitor)
Pralatrexate · Folotyn
Pralatrexate was the first drug approved specifically for relapsed peripheral T-cell lymphoma; about a third of patients respond.
ApprovedPan-HDAC inhibitor (hydroxamate)
Belinostat · Beleodaq
Belinostat is an HDAC inhibitor for relapsed peripheral T-cell lymphoma; about a quarter of patients respond, and it can be used in patients with low platelets.
ApprovedVinca alkaloid (microtubule inhibitor)
Vincristine · Oncovin / Marqibo
A plant-derived chemotherapy from the Madagascar periwinkle that has been in almost every childhood leukaemia and lymphoma regimen since the 1960s.
ApprovedAlkylating agent (nitrogen mustard)
Melphalan (including hepatic delivery system) · Alkeran / Evomela / Hepzato Kit
The myeloma chemotherapy that is also the standard high-dose conditioning before autologous transplant, and, delivered directly into the liver's blood supply or the eye, treats uveal melanoma metastases and retinoblastoma.
Similar pages
- TrialRandomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
Shares Belinostat, Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- CompanyMundipharma
Shares Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma.
- TrialA Phase III Multicenter, Randomized Study Comparing RIT Vs ASCT in Patients With Relapsed/Refractory (FL)
Shares Ibritumomab tiuxetan, Follicular lymphoma.
- TargetHistone deacetylases (HDAC)
Shares Belinostat, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TermWhat the NHS in England funds for lymphoma, appraisal by appraisal
Shares Belinostat, Pralatrexate, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma.
- CollectionLymphoma Research Foundation (LRF)
Shares Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma), Follicular lymphoma.
- TrialTucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Shares Vincristine, Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma).
- TrialA Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
Shares Vincristine, Follicular lymphoma.
cancers
drugs
ApprovedPan-HDAC inhibitor (hydroxamate)
Belinostat · Beleodaq
ApprovedRadioimmunotherapy (yttrium-90 labelled anti-CD20 antibody)
Ibritumomab tiuxetan · Zevalin
ApprovedAlkylating agent (nitrogen mustard)
Melphalan (including hepatic delivery system) · Alkeran / Evomela / Hepzato Kit
ApprovedAntifolate (DHFR inhibitor)
Pralatrexate · Folotyn
ApprovedVinca alkaloid (microtubule inhibitor)
Vincristine · Oncovin / Marqibo